Skip to main content

A ray of hope for arthritis




​Thanks to ancient science Ayurveda which came up with a unique wonder drug under the name of S.Compound.

Work on herb was started in the year 1974 and ultimately it was confirmed that the herb has great potential in inflammatory conditions. However, its role on arthritis was explored because it was the most neglected disease by the scientists and Medical fraternity. The available pain killers were causing huge harm to our body systems and some of the available pain killers were even banned in Europe.
The herbal medicine S.Compound was compared with Phenylbutazone by the scientists of Central Drug Research Institute Lucknow in the year 1983 and was found better in efficacy

Controlled Clinical trials were carried out on human beings suffering from Rheumatoid arthritis; Is not only its efficacy was confirmed but it was also found safe in long duration. The research work was published in Eastern Pharmacist which was reported by country's premier News Agency United News of India on 21.06.1982 0under the caption: Hope for arthritis patients. 

The news states Jammu Pharmaceutical firm has developed an Ayurvedic Medicine that may prove a ray of hope for arthritis patients. It was observed during trials conducted in patients suffering from chronic Rheumatoid arthritis that the drug afforded between 70 and 80 percent relief with regard to swelling in joints and tenderness, morning stiffness, walking time and patients own impression of overall disease activity. According to Eastern Pharmacist, a leading pharmaceutical journal, it appears that the drug acts on the basic pathological process responsible for the genesis of Rheumatoid arthritis.

Due to coverage in large number of Indian News Papers, Indian Health Minister gave. A statement in November 1983 that Rahul Pharma Jammu developed an Ayurvedic drug in the name of S.Compound .The main ingredient of the drug is Salai sGuggul. This drug is claimed to be very effective for the treatment of Rheumatoid arthritis.

Former Union Minister of State for Commerce Shantilal Patel while speaking to Indian Express on 29.05.2004 stated that Arthritis is one of the most painful diseases and has increased many folds due to change in life style of people, he said,based on his experiences, that the persons who live a sedentary life are the most affected people.

Continue reading​

Comments

Post a Comment

Popular posts from this blog

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing Wednesday, March 28, 2007 08:00 IST  Seema Thakral Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased ris...
Post a Comment
Read more

Combination Vaccine for Kids withdrawn

A vaccine that combines conventional MMR (Measles, Mumps, Rubella) with Chikenpox has been withdrawn in the United States due to a higher rate of seizures in children. In a study children aged 12 to 23 months who received the combined MMR cum Chickenpox vaccine had double the rate of seizures compared to children who got separate vaccine for MMR and chickenpox. This equates to one additional case of convulsion per 2000 vaccinations.
Post a Comment
Read more

BE guidelines regarding investigator

BE guidelines recommend investigator should possess appropriate medical qualification, experience for conducting pharmacokinetic studies Can chairperson of EC directly write to sponsor to clarify some of the queries of clinical trial raised in EC meeting? Dr. Sreevatsa Please see an extract from FDA's comment on IRB-sponsor relationship. The interrelationship and interaction between the research sponsor (e.g., drug, biologic and device manufacturers), the clinical investigator and the Institutional Review Board (IRB) may be very complex. The regulations do not prohibit direct sponsor-IRB contacts, although, the sponsor-IRB interaction customarily occurs through the investigator who conducts the clinical study. The clinical investigator generally provides the communication link between the IRB and the sponsor. Such linkage is agreed to by the sponsors and investigators when they sign forms FDA-1571 and FDA-1572, respectively, for drug and biologic studies or a...
Post a Comment
Read more